Compare Becton Dickinson and Co (BDX) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Becton Dickinson and Co trades at $154.5 (market cap $41.51B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $119.36. The key difference: Becton Dickinson and Co pays a 2.79% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | QQQE | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $185.39 | $122.72 |
52-Week Low | $135.49 | $96.06 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
QQQE trades at $119.15, down 1.21% on the day, with technical indicators showing a neutral overall signal. The ETF provides equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights SpaceX's potential inclusion in the Nasdaq-100, which could drive additional ETF inflows.
The equal-weight strategy offers defensive positioning during market rotations, though key financial ratios remain unavailable for analysis. Risks include market volatility and concentration in growth stocks. Analyst sentiment appears mixed with equal buy/sell signals, suggesting balanced institutional views on near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
